SCHEMBL4723129

SCHEMBL4723129

CCOc1cnn[c]c1-c1cccc2ccccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP1 P22413 1/20 0.44
S1PR1 P21453 1/20 0.44
S1PR3 Q99500 1/20 0.44
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
POLB P06746 2/20 0.38
GUSB P08236 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.36
TSHR P16473 2/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
FDPS P14324 1/20 0.35
ALOX5 P09917 1/20 0.35
DRD2 P14416 1/20 0.35
DRD4 P21917 1/20 0.35
DRD3 P35462 1/20 0.35
TLR8 Q9NR97 1/20 0.35
CHRNB4 P30926 1/20 0.34
CHRNA3 P32297 1/20 0.34
CHRNA7 P36544 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4719990 0.90 CNR1 (0.41) MEN1KMT2ATSHRTLR8
SCHEMBL4723799 0.88 HTR1B (0.43) L3MBTL1TLR8CHRNB4CHRNA3CHRNA7
SCHEMBL4721336 0.85 ALDH1A1 (0.40) MEN1KMT2ATSHRMAPTHPGD
SCHEMBL4724855 0.80 ENPP1 (0.44) ENPP1S1PR1S1PR3MEN1KMT2A
SCHEMBL4721748 0.77 GRM5 (0.39) MEN1KMT2AL3MBTL1MAPTHPGD
SCHEMBL4724628 0.73 ENPP1 (0.49) ENPP1S1PR1S1PR3GUSBTSHR
SCHEMBL10823555 0.73 ENPP1 (0.57) ENPP1S1PR1S1PR3GUSBTSHR
SCHEMBL4722698 0.72 ENPP1 (0.43) ENPP1S1PR1S1PR3GUSBTSHR
SCHEMBL4724759 0.71 ENPP1 (0.39) ENPP1S1PR1S1PR3MEN1KMT2A
SCHEMBL4723619 0.71 ENPP1 (0.39) ENPP1S1PR1S1PR3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 ENPP1 414/4885S1PR1 618/4885S1PR3 346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.